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Abstract: Nucleoprotein (NP) and matrix protein 1 (M1) are highly conserved among influenza
A viruses and have been attractive targets to develop vaccines to elicit cross-reactive cytotoxic T
lymphocytes (CTLs). Yet, external antigens are often presented on major histocompatibility complex
class II molecules and elicit humoral immune responses. In this study, we present a physical
radiofrequency adjuvant (RFA) to assist recombinant NP and M1 to elicit potent CTL responses. We
found recombinant NP/M1 immunization in the presence of RFA could elicit potent anti-NP CTLs
and confer significant protection against homologous viral challenges, while NP/M1 immunization
alone failed to elicit significant CTL responses or confer significant protection. Interestingly, RFA
failed to elicit potent anti-M1 CTL responses or anti-NP or anti-M1 antibody responses. Different from
RFA, AddaVax adjuvant was found to significantly increase NP-specific antibody responses but not
CTLs. NP/M1 immunization in the presence of RFA or AddaVax similarly reduced body weight loss,
while only the former significantly increased the survival. We further found NP/M1 immunization
in the presence of RFA did not significantly increase serum IL-6 release (a systemic inflammatory
mediator) and rather reduced serum IL-6 release after boost immunization. NP/M1 immunization
in the presence of RFA did not induce significant local reactions or increase body temperature of
mice. The high potency and safety strongly support further development of RFA-based recombinant
NP/M1 vaccine to elicit cross-protective immunity.
Keywords: radiofrequency; NP; M1; cross-presentation; adjuvant; influenza
1. Introduction
Vaccine remains the most effective and cost-effective means to control influenza [1].
Currently approved influenza vaccines mainly stimulate strain-specific humoral immune
responses against surface antigen hemagglutinin (HA) and are ineffective to protect against
strains that have undergone antigenic drifts or shifts [1,2]. As such, current influenza
vaccines need to be manufactured and immunized annually to provide updated protection
against potentially different circulating strains [1,2]. Moreover, the current influenza
vaccines are expected to be ineffective against the emergence of a pandemic viral strain [1,2].
Recently, universal influenza vaccines targeting conserved influenza internal antigens
attracted significant attention and a number of universal influenza vaccine candidates
based on internal antigens are under active development [3]. These types of vaccines
mainly induce cytotoxic T lymphocytes (CTLs) to confer cross-protection [4].
Nucleoprotein (NP) and Matrix 1 (M1) are attractive targets for universal influenza
vaccine development [5]. Studies found that M1 and NP are the immunodominant tar-
gets of cross-reactive CD4+ and CD8+ T cells against H5N1 virus in human individuals
after seasonal influenza A virus infection [6]. NP has been widely explored as universal
influenza vaccine antigens. Influenza NP gene has been inserted into viral vectors, such as
adenovirus 5 (Ad5) [7] and chimpanzee adenovirus simian adenovirus 24 (AdC7) [8], to
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develop universal influenza vaccines. Besides viral vector vaccines, NP mRNA vaccines
have been also under development to elicit cross-protective immunity [9]. Viral vector or
mRNA-based vaccines induce NP expression in host cells, which is then presented on ma-
jor histocompatibility complex (MHC) class I molecules for elicitation of NP-specific CTL
responses [7–9]. NP-specific CTLs eliminate virus-infected cells, reduce disease severity,
and promote recovery. Induction of CTL responses against multiple antigens has been
an attractive approach to increase the breadths of protection [10,11]. In fact, viral vector
vaccines targeting both NP and M1 have been also explored to induce cross-protective
immunity. One study found NP/M1-inserted replication-defective Simian Adenovirus
Vector (PanAd3) vaccine could elicit strong antibody and T-cell responses and confer pro-
tection against high-dose lethal viral challenges [12]. In another study, NP/M1-inserted
replication-deficient adenovirus and modified vaccinia virus (MVA) vaccines were devel-
oped [13]. In this study, different immunization routes and modification of vaccine use
in prime and boost immunizations were explored to elicit potent CTL responses against
heterologous viral challenges [13].
Besides the novel types of viral vector and mRNA-based vaccines, incorporation of
vaccine adjuvants into traditional protein-based vaccines may also elicit vaccine-specific
CTL responses and confer cross-protection. Considering protein-based vaccines are mainly
presented on MHC class II molecules and elicit humoral immune responses [14], the candi-
date adjuvants would need to shift the presentation of protein antigens on MHC I molecules
and induce cross-presentation. Due to the limited number of vaccine adjuvants to meet
vaccine development needs and the slow pace to develop chemical adjuvants [15–17], we
took a different approach to develop physical radiofrequency (RF) adjuvant (RFA) to boost
vaccination [18]. Physical RFA emits high-frequency electromagnetic waves on skin surface
and causes local thermal stress with potential release of damage-associated molecular
patterns (DAMPs) to alert innate immune systems to boost vaccination. Physical RFA
was found to elicit transient low-level local inflammation, while chemical adjuvants were
found to induce more significant local reactions in murine models [18]. Physical adjuvants
are also less likely to induce significant systemic or long-term side effects considering no
foreign materials enter the body.
Our recent studies found non-invasive RF treatment of the mouse skin followed
by intradermal (ID) delivery of model antigen ovalbumin (OVA) or influenza pandemic
2009 H1N1 vaccine could elicit potent humoral immune responses and at the same time
induce OVA and recombinant HA (rHA)-specific CTL responses via induction of cross-
presentation of protein antigens [18]. Furthermore, OVA-specific CTL responses induced
by ID OVA immunization in the presence of RFA conferred significant protection against
OVA-expressing E.G7 lymphoma growth in murine models [18]. This study explores
whether RFA could elicit potent CTL responses against recombinant NP and M1 protein
vaccines and confer protection against influenza viral challenges in murine models.
2. Materials and Methods
2.1. Reagents
Recombinant NP (11675-V08B) and M1 (40010-V07E) of influenza A/Puerto Rico/8/34/
Mount Sinai (H1N1) expressed by the baculovirus-insect cell expression system were pur-
chased from Sino Biological US Inc. (Wayne, PA, USA). AddaVax (a formulation similar
to MF59 for preclinical research use) was purchased from InvivoGen (San Diego, CA,
USA). Fluorescence-conjugated antibodies were purchased from BioLegend (San Diego,
CA, USA).
2.2. Mice
C57BL/6 mice (6 weeks old, male) were purchased from Charles River Laboratories
(Wilmington, MA, USA). Animals were housed in animal facilities of University of Rhode
Island (URI) and anesthetized for hair removal, RF treatment, and immunization. Animal
experiments involving influenza viruses were conducted in animal biosafety level 2 (ABSL2)
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facility of URI. All animal procedures were approved by the Institutional Animal Care and
Use Committee of URI.
2.3. RF Device
A cosmetic fractional bipolar RF device equipped with 12 × 12 array of microelectrodes
in 2 × 2 cm2 area was used as in our previous report [18]. This device has three energy
settings (low, medium, high) and high-energy setting was used in this study to induce
significant tissue stress after 1–2 min treatment. For RF treatment, a thin layer of ultrasound
gel (03–08, Parker Laboratories, Fairfield, NJ, USA) was applied on the skin surface as
recommended by manufacturer and RF device was then firmly pressed to allow treatment
tips to have a close contact with skin surface.
2.4. Immunization
Hair on the lateral dorsal skin of mice was shaved and completely removed with
the help of a hair removal lotion (Nair) as shown in our previous report [19]. Next day,
hair-free skin was exposed to RF or sham treatment followed by ID injection of a mixture
of 5 µg NP and 5 µg M1 in 20 µL (endotoxin level <1.0 EU per µg of protein) into RF
or sham-treated skin or ID injection of 20 µL PBS to serve as control. Mice were also
intramuscularly injected with the same amount of NP and M1 in the presence of AddaVax
adjuvant (1:1 volume ratio, total 40 µL) in the thigh muscle of the hind leg. Commercial
NP and M1 were dialyzed against sterile PBS for use in immunization studies. Mice were
boost immunized 3 weeks later as in prime immunization.
2.5. Antibody Titer Measurement
Serum antibody titer was measured by enzyme-linked immunosorbent assay (ELISA)
as in our previous report [19]. In detail, ELISA plates were coated with NP or M1
(0.5 µg/mL) at 4 ◦C overnight. After blocking with 5% non-fat milk, 2-serial dilutions of
immune sera were added and incubated at room temperature for 90 min. After washing in
PBS supplemented with 0.05% Tween 20 (PBST), horseradish peroxidase (HRP)-conjugated
sheep anti-mouse IgG secondary antibodies (1:2500, NA931, GE Healthcare Life Sciences)
were added and incubated at room temperature for 1 h. After washing in PBST, 1-step ultra
TMB substrates (34028, Thermo Scientific) were added and reactions were then stopped
by addition of 1M H2SO4. Optical absorbance (OD450nm) was read in a microplate reader
(Molecular Devices). Serum antibody titer was defined as the reciprocal dilution factor
that resulted in OD450nm that was ~3 times higher than the background values. For de-
tection of subtype antibody titer, HRP-conjugated anti-mouse IgG1 (046120, Invitrogen,
Thermo Fisher Scientific) and IgG2c (A90136P, Bethyl Laboratories) secondary antibodies
were used.
2.6. Cellular Immune Response
To measure vaccine-specific CD4+ and CD8+ T cells in peripheral blood mononuclear
cells (PBMCs), a small volume of blood (~ 50 µL) was collected into heparinized tubes
followed by red blood cell (RBC) lysis. PBMCs were then stimulated with 1 µg/mL NP
or M1 in the presence of 4 µg/mL anti-CD28 antibodies overnight. Next day, Brefeldin
A (420601, BioLegend) was added 5 hours before cell harvest. PBMCs were then stained
with fluorescence-conjugated anti-CD4 (RM4–5) and anti-CD8 (53–6.7) antibodies, fixed
and permeabilized, and then stained with fluorescence-conjugated anti-IFNγ (XMG1.2)
and anti-IL4 antibodies (11B11). Cells were then subjected to flow cytometry analysis in
BD FACSVerse.
2.7. Lethal Viral Challenge
Mouse-adapted influenza A/Puerto Rico/8/1934 (H1N1) viruses (NR-28652, abbre-
viated as PR8) were obtained from BEI Resources. LD50 of PR8 viruses was first deter-
mined [20]. In brief, groups of mice (n = 5) were infected with 100, 101, 102, 103, 104,
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and 105 TCID50 influenza viruses. Survival and body weight were monitored daily for
14 days. LD50 was calculated by the method of Reed and Muench [20]. For lethal viral
challenge, mice were intranasally inoculated with 4 × LD50 of influenza viruses under
light anesthesia. Body weight and survival were monitored daily for 14 days. Mice with
body weight loss more than 20% were euthanized and regarded as dead.
2.8. Cytokine Levels
Serum IL-6 levels were measured by mouse IL-6 ELISA Ready-SET-Go kit (88-7064-88,
Invitrogen).
2.9. Statistics
Values were expressed as mean ± SEM (standard error of the mean). One-way
analysis of variance (ANOVA) with Tukey’s multiple comparison test was used to compare
differences for more than two groups, except otherwise specified. P-value was calculated
by PRISM software (GraphPad, San Diego, CA, USA) and considered significant if it
was <0.05.
3. Results
3.1. RFA Enhances NP-Induced Cellular Immune Responses
Mice were subjected to prime/boost immunizations of ID NP/M1 alone or in the
presence of RFA, or IM NP/M1 in the presence of AddaVax, or ID PBS (Figure 1). Cellular
immune responses were explored one week after boost (Figure 1). Briefly, PBMCs were
isolated and stimulated with NP or M1 to evaluate percentage of IFNγ or IL4-secreting
cells in CD4+ and CD8+ T cells.
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Figure 1. Schematic illustration of experimental design.
As shown in (Figure 2A), ID NP/M1 immunization in the presence of RFA was found
to significantly increase NP-specific IFNγ+CD4+ T cells as compared to ID NP/M1 immu-
nization alone. Percentage of NP-specific IFNγ+CD4+ T cells in NP/M1/RFA group was
increased by ~3.6 folds as compared to that in NP/M1 group. IM NP/M1 immunization in
the presence of AddaVax also significantly increased percentage of NP-specific IFNγ+CD4+
T cells to a level similar to that in NP/M1/RFA group. We further found ID NP/M1
immunization in the presence of RFA also significantly increased NP-specific IFNγ+CD8+ T
cells as compared to ID NP/M1 immunization alone (Figure 2B). Percentage of NP-specific
IFNγ+CD8+ T cells in NP/M1/RFA group was increased by ~3 folds as compared to that in
NP/M1 group. Interestingly, IM NP/M1 immunization in the presence of AddaVax failed
to increase the percentage of NP-specific IFNγ+CD8+ T cells (Figure 2B). Interestingly,
M1-specific IFNγ+CD4+ T cells showed no significant difference among groups (Figure 2C).
M1-specific IFNγ+CD8+ T cells significantly increased in NP/M1 group as compared to PBS
control, while significantly reduced in NP/M1/AddaVax group as compared to NP/M1
group (Figure 2D). These results indicated RFA could significantly increase NP-induced
IFNγ-secreting CD4+ and CD8+ T cells.
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Figure 2. RFA enhances NP-specific cellular immune responses. C57BL/6 mice were subjected to
RF or sham treatment followed by ID injection of 5 µg NP and 5 µg M1 into RF (NP/M1/RFA) or
sham-treated skin (NP/M1), or IM injection of 5 µg NP and 5 µg M1 in the presence of AddaVax
(NP/M1/AddaVax), or ID injection of PBS (PBS control). Immunizations were repeated 3 weeks later.
PBMCs were collected one week after boost, stimulated with NP or M1 followed by intracellular
cytokine staining and flow cytometry analysis. Cells were first gated based on FSC and SSC and then
based on CD4 and CD8. Percentage of IFNγ-secreting cells in CD4+ and CD8+ T cells stimulated
by NP are shown in (A,B) and stimulated by M1 are shown in (C,D), respectively. n = 5. One-way
ANOVA with Fisher’s LSD test was used to compare difference between NP/M1 and other gr ups.
*, p < 0 05; **, p < 0.01; ***, p < 0.001; NS, not significant.
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measured with a mouse rectal temperature probe connected to PhysioSuite (Kent 
Scientific) as in our previous report [23]. We found there was no significant difference of 
rectal temperature among groups (Figure 4C,D). Besides systemic safety, ID NP/M1 
immunization in the presence of RFA induced minimal local reactions, as observed in our 
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Figure 3. RFA had a minimal effect on NP and M1-induced antibody responses. Anti-NP and anti-M1
antibody responses were evaluated 3 weeks after boost. (A) Serum anti-NP IgG titer. (B) Serum
anti-M1 IgG titer. (C) Serum anti-NP IgG1 titer. (D) Serum anti-NP IgG2c titer. n = 5. One-way
ANOVA with Fisher’s LSD test was used to compare differences between NP/M1 and other groups.
*, p < 0.05; **, p < 0.01; ***, p < 0.001; NS, not significant.
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and 10 (Table 1).
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Figure 5. Protection against body weight loss after lethal viral challenges. Mice were intranasally
challenged with 4 × LD50 of mouse-adapted PR8 viruses 28 days after boost. Body weight loss was
monitored daily for 14 days. n = 5.
Table 1. Statistical analysis of percent body weight change between groups.
NP/M1 NP/M1/RFA NP/M1/AddaVax Reference Group
Day 8 NS p < 0.05 p < 0.01 PBS control
Day 9 - p < 0.05 p < 0.05 NP/M1
Day 10 - p < 0.05 < 0.05 NP/M1
(Note: Two-way ANOVA with Du nett’s multiple comparison test was used to compare differences between
groups. NS, not significant).
3.5. RFA Increased NP/M1-Induced Protection against Lethality
Survival of mice after viral challenges was also explored. All mice in PBS control
group died or reached humane endpoint of euthanasia within 9 days. Two out of 5 mice in
NP/M1 group and 3 out of 5 mice in NP/M1/AddaVax group survived the lethal viral
challenge, while 4 out of 5 mice in NP/M1/RFA group survived the challenge (Figure 6).
ID NP/M1 immunization alone or IM NP/M1 immunization in the presence of AddaVax
failed to significantly increase the survival of mice, while ID NP/M1 immunization in the
presence of RFA significantly increased the survival of mice (Figure 6).
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Figure 6. Protection against lethality after lethal viral challenges. Survival of virus-challenged mice
was monitored for 14 days. Mice were regarded as dead if their body weight loss was more than 20%.
n = 5. Log-rank (Mantel-Cox) test was used to compare differences of survival between PBS control
and other groups. **, p < 0.01. NS: not significant.
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4. Discussion
This study indicated RFA was effective to boost recombinant NP/M1 vaccination.
RFA was found to significantly increase NP-specific CTL responses and NP/M1-induced
protection against homologous viral challenges. External proteins are mainly presented on
MHC class II molecules and elicit humoral immune responses. The induction of significant
CTL responses against recombinant NP hinted RFA enabled cross-presentation of external
antigens. In our previous report, we found RFA also enabled cross-presentation of OVA and
rHA to induce potent CTL responses [18]. Interestingly, RFA failed to induce significant
M1-specific CTL responses in this study. The underlying reason remained unknown but
may reflect the uniqueness of M1 as compared to the other three antigens (OVA, rHA, and
NP). For example, M1 failed to elicit potent antibody responses, while the other antigens
could elicit potent antibody responses. M1 alone elicited potent CTL responses, while
the other antigens alone failed to elicit potent CTL responses. In our study, we found
RFA also significantly enhanced NP-specific IFNγ+CD4+ T cells. The potential role of
NP-specific IFNγ+CD4+ T cells in induction of potent IFNγ+CD8+ T cells and overall
protection remains to be explored.
Our study compared relative immunogenicity and protective efficacy of ID NP/M1
immunization in the presence of RFA to IM NP/M1 immunization in the presence of
AddaVax. Due to the high risk of AddaVax adjuvant to induce significant local reactions
following ID delivery [24], IM route was used for delivery of NP/M1 in the presence of
AddaVax adjuvant in our study. We found NP/M1 immunization in the presence of RFA
significantly increased NP-specific CTL responses, while NP/M1 immunization in the
presence of AddaVax significantly increased NP-specific antibody responses. Interestingly,
NP/M1 immunization in the presence of AddaVax also induced significant protection
against body weight loss, similar to that induced by NP/M1 immunization in the presence
of RFA. The significant protection observed in NP/M1/AddaVax group was likely to be
mediated by anti-NP antibody responses. In support, non-neutralizing anti-NP antibodies
have been found to also confer protection against viral challenges [25]. Interestingly,
NP/M1 immunization in the presence of RFA significantly increased survival of mice
as compared to PBS control, while NP/M1 immunization in the presence of AddaVax
failed to do so. We only challenged homologous PR8 virus where the recombinant NP and
M1 were originated from. However, due to the high homology of NP and M1 sequences
among influenza A viruses, we believe NP/M1 immunization in the presence of RFA may
confer similar protections against other influenza A viruses, which will be explored in the
near future. The relative contribution of anti-M1 immune responses to overall protection
in NP/M1/RFA group will be also characterized to support the dual antigen approach.
Furthermore, the duration of NP-specific IFNγ+CD8+ T cells will be also assessed to explore
the ability of NP/M1 immunization in the presence of RFA to elicit durable CTL responses
and long-term protection.
RFA was safe to boost vaccination. Serum IL-6 levels were used in our study as
a systemic inflammatory mediator due to its close association with systemic adverse
reactions of vaccines [21]. RFA failed to significantly increase NP/M1-induced systemic
IL-6 release in prime immunization and rather reduced NP/M1-induced systemic IL-6
release in boost immunization. The reason that RFA reduced NP/M1-induced systemic
IL-6 release remained to be explored but may reflect the uniqueness of the physical RFA
to boost ID vaccination considering physical RFA briefly treats the skin without causing
overt reactions. Our previous studies found RFA only induced transient low-level local
inflammation, while ID injection of chemical adjuvants (Alum, MF59, MPL) induced lasting
and more significant local inflammation [18].
Other strategies have been explored to elicit anti-NP and anti-M1 CTL responses
and confer protection against influenza viral infection. These strategies include the de-
velopment of DNA and viral vector vaccines and through virus-like particle (VLP) plat-
forms [1,10,26–28]. As compared to these strategies, the development of adjuvants to aid
recombinant NP and M1 to elicit CTL responses has the advantage that recombinant NP
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and M1 represents traditional vaccine type and currently we are lacking a universal VLP
platform to present influenza internal antigens to elicit potent CTL responses. The physical
RFA represents a promising adjuvant capable of enhancing NP-specific CTL responses.
Our previous study also indicated RFA was at least comparable to CpG and AddaVax to
elicit OVA and rHA-specific CTL responses [18]. Besides its high potency to induce CTL
responses, RFA also has below advantages to boost vaccination. First, it does not need to
modify vaccine manufacturing considering it is used to elicit tissue stress with potential
release of endogenous danger signals to enhance vaccine-induced immune responses.
Second, it induces minimal local and systemic adverse reactions. RFA device can also be
used repeatedly for cost-effective adjuvantation.
5. Conclusions
Conserved internal antigen-based universal T-cell vaccines are under development
to induce cross-reactive CTL responses and confer cross-protection against influenza A
viruses. Vaccine adjuvants hold a great promise to induce cross-presentation of influenza
internal antigens and elicit potent CTL responses. Yet, the majority of approved adjuvants
mainly enhance humoral immune responses. We took advantage of our recently developed
physical RFA capable of elicitation of potent CTL responses against protein antigens to
develop recombinant NP/M1-based universal T-cell vaccines. Results from the current
study support the potency and safety of RFA to aid recombinant NP/M1 to induce potent
NP-specific CTL responses and protection against homologous viral challenges in murine
models. Our data support further development of the physical RFA and recombinant
NP/M1-based universal T-cell vaccine.
Author Contributions: X.C. and Y.L. designed experiments; Y.L., Z.L., Y.Z. conducted experiments
and acquired data; X.C. and Y.L. analyzed data; X.C. and Y.L. wrote the manuscript. All authors have
read and agreed to the published version of the manuscript.
Funding: This research was funded by the National Institutes of Health grants AI139473 (to X.C.).
Microplate reader and BD FACSVerse used in this work are supported by an Institutional Develop-
ment Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes
of Health grant P20GM103430.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Conflicts of Interest: The authors declare no competing interest.
References
1. Wong, S.S.; Webby, R.J. Traditional and new influenza vaccines. Clin. Microbiol. Rev. 2013, 26, 476–492. [CrossRef]
2. Yamayoshi, S.; Kawaoka, Y. Current and future influenza vaccines. Nat. Med. 2019, 25, 212–220. [CrossRef]
3. Ostrowsky, J.; Arpey, M.; Moore, K.; Osterholm, M.; Friede, M.; Gordon, J.; Higgins, D.; Molto-Lopez, J.; Seals, J.; Bresee, J.
Tracking progress in universal influenza vaccine development. Curr. Opin. Virol. 2020, 40, 28–36. [CrossRef]
4. Uchida, T. Development of a cytotoxic T-lymphocyte-based, broadly protective influenza vaccine. Microbiol. Immunol. 2011, 55,
19–27. [CrossRef] [PubMed]
5. Cargnelutti, D.E.; Sanchez, M.V.; Mattion, N.M.; Scodeller, E.A. Development of a universal CTL-based vaccine for influenza.
Bioengineered 2013, 4, 374–378. [CrossRef]
6. Lee, L.Y.; Ha, D.L.A.; Simmons, C.; de Jong, M.D.; Chau, N.V.V.; Schumacher, R.; Peng, Y.C.; McMichael, A.J.; Farrar, J.J.; Smith,
G.L.; et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in
healthy individuals. J. Clin. Investig. 2008, 118, 3478–3490. [CrossRef] [PubMed]
7. Epstein, S.L.; Kong, W.P.; Misplon, J.A.; Lo, C.Y.; Tumpey, T.M.; Xu, L.; Nabel, G.J. Protection against multiple influenza A
subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 23, 5404–5410. [CrossRef] [PubMed]
8. Roy, S.; Kobinger, G.P.; Lin, J.; Figueredo, J.; Calcedo, R.; Kobasa, D.; Wilson, J.M. Partial protection against H5N1 influenza in
mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 2007, 25, 6845–6851. [CrossRef]
Vaccines 2021, 9, 1382 11 of 11
9. Joe, P.T.; Christopoulou, I.; van Hoecke, L.; Schepens, B.; Ysenbaert, T.; Heirman, C.; Thielemans, K.; Saelens, X.; Aerts, J.L.
Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice. J. Transl.
Med. 2019, 17, 242. [CrossRef]
10. McMahon, M.; Asthagiri Arunkumar, G.; Liu, W.C.; Stadlbauer, D.; Albrecht, R.A.; Pavot, V.; Aramouni, M.; Lambe, T.; Gilbert,
S.C.; Krammer, F. Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets
Against Influenza Virus Challenge. Front. Immunol. 2019, 10, 2005. [CrossRef]
11. Asthagiri; Arunkumar, G.; McMahon, M.; Pavot, V.; Aramouni, M.; Ioannou, A.; Lambe, T.; Gilbert, S.; Krammer, F. Vaccination
with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in
mice. Vaccine 2019, 37, 5567–5577. [CrossRef] [PubMed]
12. Vitelli, A.; Quirion, M.R.; Lo, C.Y.; Misplon, J.A.; Grabowska, A.K.; Pierantoni, A.; Ammendola, V.; Price, G.E.; Soboleski, M.R.;
Cortese, R.; et al. Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived
from the bonobo Pan paniscus. PLoS ONE 2013, 8, e55435. [CrossRef] [PubMed]
13. Lambe, T.; Carey, J.B.; Li, Y.; Spencer, A.J.; van Laarhoven, A.; Mullarkey, C.E.; Vrdoljak, A.; Moore, A.C.; Gilbert, S.C. Immunity
against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1. Sci. Rep.
2013, 3, 1443. [CrossRef]
14. Neefjes, J.; Jongsma, M.L.; Paul, P.; Bakke, O. Towards a systems understanding of MHC class I and MHC class II antigen
presentation. Nat. Rev. Immunol. 2011, 11, 823–836. [CrossRef] [PubMed]
15. McKee, A.S.; Marrack, P. Old and new adjuvants. Curr. Opin. Immunol. 2017, 47, 44–51. [CrossRef] [PubMed]
16. Lee, S.; Nguyen, M.T. Recent advances of vaccine adjuvants for infectious diseases. Immune. Netw. 2015, 15, 51–57. [CrossRef]
17. Nanishi, E.; Dowling, D.J.; Levy, O. Toward precision adjuvants: Optimizing science and safety. Curr. Opin. Pediatr. 2020, 32,
125–138. [CrossRef]
18. Cao, Y.; Zhu, X.; Hossen, M.N.; Kakar, P.; Zhao, Y.; Chen, X. Augmentation of vaccine-induced humoral and cellular immunity by
a physical radiofrequency adjuvant. Nat. Commun. 2018, 9, 3695. [CrossRef]
19. Li, Z.; Cao, Y.; Li, Y.; Zhao, Y.; Chen, X. Vaccine delivery alerts innate immune systems for more immunogenic vaccination. JCI
Insight. 2021, 6, e144627. [CrossRef]
20. Cottey, R.; Rowe, C.A.; Bender, B.S. Influenza virus. In Current Protocols in Immunology; Wiley: Hoboken, NJ, USA, 2001.
21. Herve, C.; Laupeze, B.; Del.Giudice, G.; Didierlaurent, A.M.; Tavares Da Silva, F. The how’s and what’s of vaccine reactogenicity.
NPJ Vaccines 2019, 4, 39. [CrossRef]
22. Huang, C.F.; Chiu, S.Y.; Huang, H.W.; Cheng, B.H.; Pan, H.M.; Huang, W.L.; Chang, H.H.; Liao, C.C.; Jiang, S.T.; Su, Y.C. A
reporter mouse for non-invasive detection of toll-like receptor ligands induced acute phase responses. Sci. Rep. 2019, 9, 19065.
[CrossRef] [PubMed]
23. Zhao, Y.; Li, Z.; Zhu, X.; Cao, Y.; Chen, X. Improving immunogenicity and safety of flagellin as vaccine carrier by high-density
display on virus-like particle surface. Biomaterials 2020, 249, 120030. [CrossRef]
24. Chen, X.; Wu, M.X. Laser vaccine adjuvant for cutaneous immunization. Expert. Rev. Vaccines 2011, 10, 1397–1403. [CrossRef]
25. Carragher, D.M.; Kaminski, D.A.; Moquin, A.; Hartson, L.; Randall, T.D. A novel role for non-neutralizing antibodies against
nucleoprotein in facilitating resistance to influenza virus. J. Immunol. 2008, 181, 4168–4176. [CrossRef] [PubMed]
26. Lee., L.Y.Y.; Izzard, L.; Hurt, A.C. A Review of DNA Vaccines Against Influenza. Front. Immunol. 2018, 9, 1568. [CrossRef]
27. Quan, F.S.; Kim, M.C.; Lee, B.J.; Song, J.M.; Compans, R.W.; Kang, S.M. Influenza M1 VLPs containing neuraminidase induce
heterosubtypic cross-protection. Virology 2012, 430, 127–135. [CrossRef]
28. Wang, B.Z.; Xu, R.; Quan, F.S.; Kang, S.M.; Wang, L.; Compans, R.W. Intranasal immunization with influenza VLPs incorporating
membrane-anchored flagellin induces strong heterosubtypic protection. PLoS ONE 2010, 5, e13972. [CrossRef] [PubMed]
